A cheap drug that cuts heart attacks and strokes by nearly one in ten
An ancient remedy for joint pain has quietly revealed a new purpose: protecting the heart. A sweeping review of nearly 23,000 patients across 12 rigorous trials has confirmed that low-dose colchicine — a centuries-old gout treatment — meaningfully reduces heart attacks and strokes in people already living with cardiovascular disease. The mechanism is inflammation, that slow-burning biological fire long implicated in the erosion of blood vessels, and the drug's affordability and availability make this not merely a clinical finding but a question of global equity in medicine.
- Cardiovascular disease remains one of humanity's most relentless killers, and for high-risk patients, every additional tool against another event carries enormous weight.
- The Cochrane review — covering 12 randomized trials and nearly 23,000 patients — found colchicine prevented nine heart attacks and eight strokes per thousand people treated, numbers modest in isolation but transformative at population scale.
- Unlike costly novel therapies, colchicine is already on pharmacy shelves worldwide at low cost, making its repurposing a rare convergence of strong evidence and practical accessibility.
- Safety concerns, historically a shadow over colchicine, proved minimal — gastrointestinal discomfort appeared in some patients, but no serious adverse events were identified across the analysis.
- The field now faces a pivotal question: whether cardiologists and health systems will move swiftly to integrate this evidence into standard prevention protocols, particularly for patients who cannot afford cutting-edge alternatives.
A gout drug that has been sitting on pharmacy shelves for centuries may be one of cardiology's most overlooked assets. A comprehensive Cochrane review — drawing on 12 randomized controlled trials and nearly 23,000 patients — has found that low-dose colchicine, typically 0.5 milligrams once or twice daily, reduces heart attacks and strokes in people with established cardiovascular disease. For every thousand patients treated, nine fewer suffered heart attacks and eight fewer had strokes. In a group of 200 cardiac patients, that translates to roughly two fewer heart attacks and two fewer strokes — modest in isolation, but meaningful across a lifetime of risk.
The drug works by targeting chronic, low-grade inflammation — the smoldering biological process that damages blood vessels and encourages clot formation at the root of most cardiovascular events. Colchicine, long used to quiet the inflammatory storms of gout, appears to dampen this same process in the heart and arteries. Trial participants, predominantly men between 57 and 74, were tracked over months and years, with half receiving colchicine and half receiving a placebo or standard care alone.
The safety picture was reassuring. No serious adverse events emerged from the analysis. Some patients reported mild gastrointestinal complaints — nausea, diarrhea — but nothing that drove significant numbers to abandon the drug. Co-lead author Dr. Ramin Ebrahimi noted that reductions of this scale carry real meaning for patients navigating lifelong cardiovascular risk.
What distinguishes this finding is not novelty but recognition. Colchicine is old, inexpensive, and globally available — a repurposed tool rather than a laboratory breakthrough. That distinction matters enormously for health systems and patients in parts of the world where advanced cardiac therapies remain financially out of reach. The question now pressing on the medical community is whether this evidence will translate into routine prescribing, and whether prevention guidelines will be rewritten to reflect what a centuries-old remedy can still teach us.
A cheap, widely available gout medication appears to cut the risk of heart attacks and strokes in people with established heart disease. That's the finding of a comprehensive review of 12 randomized controlled trials involving nearly 23,000 patients, published by the Cochrane Collaboration, an independent research organization known for rigorous analysis of medical evidence.
The drug is colchicine, taken at low doses—typically 0.5 milligrams once or twice daily. Researchers found that patients who took it for at least six months experienced fewer cardiovascular events than those who didn't. The numbers are modest but meaningful: for every thousand people treated, nine fewer suffered heart attacks and eight fewer had strokes. In practical terms, among a group of 200 cardiovascular patients where you'd normally expect seven heart attacks and four strokes, low-dose colchicine could prevent roughly two of each.
What makes this finding significant is both the mechanism and the simplicity. Heart disease and stroke are often driven by chronic, low-grade inflammation in the body—a smoldering fire that damages blood vessels and promotes clot formation. Colchicine, which has been used for centuries to treat gout, is an anti-inflammatory agent. By dampening this inflammatory response, it appears to reduce the likelihood of the catastrophic events that kill or disable cardiovascular patients.
The trials included in the review were rigorous. Most participants were men (roughly 80 percent), with average ages ranging from 57 to 74 years. Half received colchicine; the other half received either a placebo or continued their usual care without the added drug. Researchers tracked what happened over months and years, looking for both benefits and harms.
The safety profile was reassuring. The review found no increase in serious adverse events among those taking colchicine. Some patients did report stomach or digestive side effects—nausea, diarrhea, the kinds of gastrointestinal complaints that can accompany the drug—but these were generally mild and temporary, not the kind of thing that forced people to stop taking it.
Dr. Ramin Ebrahimi, a co-lead author of the review from the University Medicine Greifswald in Germany, framed the finding in terms of what it means for patients living with the constant threat of another cardiac event. "Reductions like this can make a real difference for patients who live with ongoing, lifelong cardiovascular risk," he said. For someone who has already had a heart attack or stroke, or who carries the diagnosis of serious heart disease, the prospect of a low-cost, well-tolerated medication that measurably lowers the odds of another event is genuinely valuable.
What's particularly striking is that colchicine is not a new drug. It's been around for decades, inexpensive, and already on pharmacy shelves worldwide. This isn't a breakthrough in the sense of a novel compound emerging from a laboratory. It's a repurposing—taking an old tool and recognizing a new job it can do. That has implications for access and affordability, especially in parts of the world where expensive, cutting-edge cardiac medications are out of reach. The question now is whether cardiologists will begin prescribing it more routinely for high-risk patients, and whether health systems will incorporate it into their standard prevention protocols.
Citações Notáveis
Reductions like this can make a real difference for patients who live with ongoing, lifelong cardiovascular risk.— Dr. Ramin Ebrahimi, University Medicine Greifswald, Germany
A Conversa do Hearth Outra perspectiva sobre a história
Why does inflammation matter so much in heart disease? It seems like a secondary thing.
It's actually central. When your arteries are inflamed, the plaques inside them become unstable and more likely to rupture. That rupture triggers a clot, which blocks blood flow. Inflammation is the match; the clot is the fire.
And colchicine just... calms that down?
It does. It's been used for gout because it suppresses the inflammatory cascade—the body's overreaction to uric acid crystals. Turns out that same mechanism helps with the inflammation driving cardiovascular disease.
The numbers seem small. Nine fewer heart attacks per thousand people. Is that actually worth taking a drug for?
It depends on your risk. If you've already had one heart attack, you're at high risk for another. For you, nine fewer per thousand means real protection. And the drug is cheap and well-tolerated, so the cost-benefit is favorable.
What about the digestive side effects? You said they were mild, but mild is relative.
True. Some people get diarrhea or nausea. But the review found these were usually temporary and didn't cause people to stop the medication. That's different from, say, a drug that makes you feel terrible every day.
Why hasn't this been standard practice already if the evidence is this clear?
The evidence is relatively recent. These trials have been accumulating over the past decade or so. Colchicine wasn't on cardiologists' radar as a prevention tool until researchers started testing it systematically. Now that a major review has synthesized the data, that's likely to change.
What happens next? Does this become standard care?
That depends on adoption. Doctors need to know about it, guidelines need to recommend it, and health systems need to make it accessible. The evidence is there. The barrier now is awareness and implementation.